Anti-CD96 antibody - Samyang Biopharm/Talix Therapeutics
Alternative Names: Anti-CD96 antibody - Talix Therapeutics/Samyang BiopharmLatest Information Update: 09 Apr 2025
At a glance
- Originator Talix Therapeutics
- Developer Samyang Biopharm USA; Talix Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Apr 2025 Discontinued - Preclinical for Cancer in Belgium (Parenteral), before April 2025
- 09 Apr 2025 Discontinued - Preclinical for Cancer in USA (Parenteral), before April 2025
- 28 Jan 2024 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)